Author

Adriaan A. Van Bodegraven

THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS - TUMMY TRIAL
THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS - TUMMY TRIAL

Adriaan A. Van Bodegraven  et al.

IMPLICATIONS OF TIOGUANINE DOSING IN IBD PATIENTS WITH A TPMT DEFICIENCY
IMPLICATIONS OF TIOGUANINE DOSING IN IBD PATIENTS WITH A TPMT DEFICIENCY

Adriaan A. Van Bodegraven  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Adriaan A. Van Bodegraven  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Adriaan A. Van Bodegraven  et al.

DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS

Adriaan A. Van Bodegraven  et al.

THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ
THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ

Adriaan A. Van Bodegraven  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Adriaan A. Van Bodegraven  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

Adriaan A. Van Bodegraven  et al.

Item 1 - 8 / 8
1